Matthew Allaway, DO, Discusses Transperineal Biopsy Approach for Prostate Cancer
Matthew Allaway, DO, detailed benefits of using an emerging transperineal biopsy approach to identify prostate cancer in hard to access areas of a patient’s prostate.
On an episode of Inside the Practice as part of Medical World News, Matthew Allaway, DO, founder and chief executive officer at Perineologic, spoke with CancerNetwork® about a prostate cancer biopsy technique that uses a transperineal approach to better detect cancer in harder to reach areas of the prostate. Along with this, Allaway touched on the American Cancer Society’s annual “Cancer Facts & Figures 2022” report and detailed the important findings from a companion study.
The new technique uses 2 needle sticks compared to 12 sticks with a standard transrectal biopsy. Moreover, the transperineal approach has a reduced risk of complications such as pain, bleeding and urinary retention.
“Historically, the prostate biopsy was performed by placing an ultrasound probe in the patient’s rectum so you could see the prostate. Then, with the probe in that position, you slide a biopsy needle within a needle guide that then passes through the rectal wall to get into the prostate,” Allaway explained regarding standard prostate biopsy techniques.
Reference
Cancer facts & figures 2022. American Cancer Society. 2022. Accessed January 28, 2022. https://tinyurl.com/5rdc6nbc
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
